ED

Elizabeth Douville

Life sciences executive

Montreal, Quebec

Invests in

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2023

  • President & CEO

    2023

2011

  • Founder

    2011

    AmorChem is a leading early-stage venture capital investing in research innovation and creating next-gen biotech companies in life sciences. The fund has 95M$ under management for pre-seed, seed and Series A investments.

  • Chair

    2019

  • Board Member

    2016 - 2019

  • Board Member

    2017

    Corbin Therapeutics develops USP15 inhibitors to treat and manage neuroinflamation.

  • Board Member

    2020

    SemaThera develops anti-SEMA3A biologics to treat diabetic macular edema.

  • Board Observer

    2018 - 2020

2018 - 2022

  • Board Observer

    2018 - 2022

    Inversago Pharma develops next gen CB1 inverse agonists to treat Prader-Willi Syndrome

2015 - 2020

  • Board Member

    2015 - 2020

2013 - 2018

  • Board Member

    2013 - 2018